BR112022019020A2 - Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas - Google Patents

Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas

Info

Publication number
BR112022019020A2
BR112022019020A2 BR112022019020A BR112022019020A BR112022019020A2 BR 112022019020 A2 BR112022019020 A2 BR 112022019020A2 BR 112022019020 A BR112022019020 A BR 112022019020A BR 112022019020 A BR112022019020 A BR 112022019020A BR 112022019020 A2 BR112022019020 A2 BR 112022019020A2
Authority
BR
Brazil
Prior art keywords
masked
methods
fusion proteins
compositions
treating
Prior art date
Application number
BR112022019020A
Other languages
English (en)
Portuguese (pt)
Inventor
Volkers Gesa
Spreter Von Kreudenstein Thomas
Afacan Nicole
Desjardins Genevieve
Douda David
Blackler Ryan
Original Assignee
Zymeworks Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zymeworks Inc filed Critical Zymeworks Inc
Publication of BR112022019020A2 publication Critical patent/BR112022019020A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5434—IL-12
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112022019020A 2020-03-23 2021-03-23 Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas BR112022019020A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062993334P 2020-03-23 2020-03-23
US202163146567P 2021-02-05 2021-02-05
PCT/CA2021/050383 WO2021189139A1 (en) 2020-03-23 2021-03-23 Masked il12 fusion proteins and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112022019020A2 true BR112022019020A2 (pt) 2023-02-07

Family

ID=77890776

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112022019020A BR112022019020A2 (pt) 2020-03-23 2021-03-23 Proteínas de fusão de il12 mascaradas e métodos de uso das mesmas

Country Status (10)

Country Link
US (1) US20230122079A1 (enExample)
EP (1) EP4126972A4 (enExample)
JP (1) JP7773991B2 (enExample)
KR (1) KR20230024252A (enExample)
CN (1) CN115529826A (enExample)
AU (1) AU2021240872A1 (enExample)
BR (1) BR112022019020A2 (enExample)
CA (1) CA3147126A1 (enExample)
MX (1) MX2022011676A (enExample)
WO (1) WO2021189139A1 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200089312A (ko) 2017-11-28 2020-07-24 추가이 세이야쿠 가부시키가이샤 리간드 결합 활성을 조정 가능한 리간드 결합 분자
EP3981428A4 (en) 2019-06-05 2023-07-12 Chugai Seiyaku Kabushiki Kaisha Protease substrate, and polypeptide including protease cleavage sequence
CN115943210A (zh) 2020-01-20 2023-04-07 中外制药株式会社 配体结合融合蛋白
BR112022019708A2 (pt) * 2020-04-01 2022-12-20 Xilio Dev Inc Citocina il-12 mascarada, produtos de clivagem, ácidos nucleicos, vetor, célula hospedeira, composições, kit, método de produção de uma citocina il-12 mascarada e métodos de tratamento ou prevenção de câncer
AU2021254283B2 (en) 2020-04-10 2025-12-11 Cytomx Therapeutics, Inc. Activatable cytokine constructs and related compositions and methods
CA3178657A1 (en) * 2020-05-19 2021-11-25 William Winston Activatable il-12 polypeptides and methods of use thereof
EP4251187A4 (en) 2020-11-25 2025-09-10 Xilio Dev Inc TUMOR-SPECIFIC CLASSIBLE LINKERS
US20250051413A1 (en) * 2021-01-12 2025-02-13 Askgene Pharma Inc. Chimeric molecules comprising il-12 agonist polypeptide
KR20230157448A (ko) 2021-03-16 2023-11-16 싸이톰스 테라퓨틱스, 인크. 마스킹된 활성화 가능한 사이토카인 작제물 및 관련 조성물 및 방법
AU2022314734A1 (en) 2021-07-19 2024-02-08 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
JP2024535925A (ja) * 2021-09-29 2024-10-02 ザイムワークス ビーシー インコーポレイテッド 修飾されたインターロイキンｐ４０サブユニットタンパク質及びその使用方法
WO2023141601A1 (en) * 2022-01-20 2023-07-27 Repertoire Immune Medicines, Inc. Cd8-targeted il-12 fusion proteins
EP4372000B1 (en) * 2022-02-15 2026-06-17 Tagworks Pharmaceuticals B.V. Masked il12 protein
WO2023161853A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Activatable il-18 polypeptides
CN120035602A (zh) * 2022-06-17 2025-05-23 辉瑞公司 Il-12变体、抗-pd1抗体、融合蛋白及其用途
WO2024148369A1 (en) * 2023-01-07 2024-07-11 Lyell Immunopharma, Inc. Targeted il-12 affinity variants
WO2024150175A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated proteins and methods of use
WO2024150174A1 (en) 2023-01-11 2024-07-18 Bright Peak Therapeutics Ag Conditionally activated immunocytokines and methods of use
AU2024207005A1 (en) * 2023-01-13 2025-08-28 Regeneron Pharmaceuticals, Inc. Il12 receptor agonists and methods of use thereof
WO2024153768A1 (en) * 2023-01-20 2024-07-25 Boehringer Ingelheim International Gmbh Il-12 fc fusion proteins
TW202517789A (zh) * 2023-07-04 2025-05-01 香港商禮邦醫藥（香港）有限公司 Ｋｌｋ１融合蛋白質的製備方法
WO2025041101A1 (en) 2023-08-23 2025-02-27 Bright Peak Therapeutics Ag Activatable il-18 immunocytokines and uses thereof
CN119823266A (zh) * 2023-10-13 2025-04-15 英脉德医疗科技(广东)有限公司 肿瘤微环境特异激活的cd47抗体
CN122349538A (zh) * 2023-12-07 2026-07-07 上海药明生物技术有限公司 针对il-12受体的异二聚体蛋白
KR20260114559A (ko) * 2023-12-08 2026-07-22 아뮤닉스 파마슈티컬스, 인크. 프로테아제 활성화가능 사이토카인 및 이의 제조 및 사용 방법
AU2024407051A1 (en) 2023-12-18 2026-07-30 Genzyme Corporation Il-12 loss of potency muteins
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof
CN117838836B (zh) * 2024-01-11 2024-06-28 广州医科大学附属第二医院 白介素39在防治血小板减少症中的应用
WO2025160083A1 (en) * 2024-01-22 2025-07-31 Onko-Innate Pty Ltd Targeted low potency il-12 fc fusion proteins and uses thereof
WO2025242835A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of cancer
WO2025242836A1 (en) * 2024-05-22 2025-11-27 Ose Immunotherapeutics Molecules comprising masking linkers and uses thereof for the treatment of auto-immune or inflammatory diseases and disorders
WO2026020161A1 (en) * 2024-07-19 2026-01-22 Cytomx Therapeutics, Inc. Activatable il-12 constructs and related compositions and methods
WO2026083296A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-18, vegf binding domains, and pd-1 binding domains
WO2026083295A1 (en) 2024-10-16 2026-04-23 Bright Peak Therapeutics Ag Trispecific compositions comprising il-2, vegf binding domains, and pd-1 binding domains

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3543256A1 (en) * 2009-01-12 2019-09-25 Cytomx Therapeutics Inc. Modified antibody compositions, methods of making and using thereof
IL300408B2 (en) * 2015-01-20 2025-11-01 Cytomx Therapeutics Inc Matrix metalloprotease-cleavable and serine protease cleavable substrates and methods of use thereof
EP3436477A2 (en) * 2016-03-29 2019-02-06 Janssen Biotech, Inc. Method of treating psoriasis with increased interval dosing of anti-il12 and/or -23 antibody
US10906957B2 (en) * 2016-09-27 2021-02-02 Epicentrx, Inc. Immunomodulatory fusion proteins
CA3115461A1 (en) * 2018-03-09 2019-09-12 AskGene Pharma, Inc. Novel cytokine prodrugs
WO2019222296A1 (en) * 2018-05-14 2019-11-21 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
MX2020014290A (es) * 2018-06-22 2021-08-05 Cugene Inc Farmacos bioactivables a base de citoquinas y métodos de usos de los mismos.
SG11202013248YA (en) * 2018-07-31 2021-02-25 Amgen Inc Pharmaceutical formulations of masked antibodies
CN113286812B (zh) * 2018-09-27 2025-05-30 西里欧发展公司 掩蔽型细胞因子多肽
CA3126707A1 (en) * 2019-01-29 2020-08-06 Gritstone Bio, Inc. Multispecific binding proteins
WO2021062406A1 (en) * 2019-09-28 2021-04-01 AskGene Pharma, Inc. Cytokine prodrugs and dual-prodrugs
CN110777115B (zh) * 2019-11-21 2020-08-21 北京启辰生生物科技有限公司 用于促进辅助T细胞产生TNF-α细胞因子的工程化DC细胞及方法
KR20230042315A (ko) * 2020-07-20 2023-03-28 자임워크스 비씨 인코포레이티드 리간드-수용체 쌍 및 생물학적 기능성 단백질을 포함하는 융합 단백질

Also Published As

Publication number Publication date
WO2021189139A1 (en) 2021-09-30
AU2021240872A1 (en) 2022-11-17
US20230122079A1 (en) 2023-04-20
JP7773991B2 (ja) 2025-11-20
CA3147126A1 (en) 2021-09-30
KR20230024252A (ko) 2023-02-20
CN115529826A (zh) 2022-12-27
EP4126972A1 (en) 2023-02-08
EP4126972A4 (en) 2024-05-01
JP2023518518A (ja) 2023-05-01
MX2022011676A (es) 2023-03-08

Similar Documents

Publication Publication Date Title
MX2022011676A (es) Proteinas de fusion de il12 con enmascaramiento y metodos para su uso.
AU2018236742B2 (en) Compositions of adenosine deaminase-2 (ada2), variants thereof and methods of using same
CY1125772T1 (el) Μακροκυκλικες ενωσεις για τη θεραπευτικη αντιμετωπιση νοσων
EP4566621A3 (en) Dll3/cd3 binding proteins for the treatment of cancer
BR112022008858A2 (pt) Composto, composição farmacêutica e métodos para inibir sos1 em um sujeito, para inibir a interação de sos1 e uma proteína, para tratar ou prevenir uma doença e para tratar ou prevenir câncer
MX2021014007A (es) Proteinas de union a epcam y metodos de uso.
MX2024014142A (es) Novedosos inhibidores de molecula peque?a de factores de transcripcion tead
CR20190063A (es) 3-metil pirazinas 2,5-disustituídas y 3-metil pirazinas 2,5,6-trisustituídas como inhibidores alostéricos de shp2
ECSP20046463A (es) Compuestos, composiciones y métodos para tratar enfermedades que involucren tejidos con enfermedades ácidas o hipóxicas
MX2020003915A (es) Proteinas trispecificas y metodos de uso.
BR112022004972A2 (pt) Anticorpos, ácidos nucleicos isolados, células hospedeiras isoladas, métodos de produção de um anticorpo, de produção de um anticorpo biespecífico e de tratamento de um indivíduo, anticorpos biespecíficos, composição farmacêutica, anticorpo, anticorpo biespecífico ou composição farmacêutica, combinação de um anticorpo, uso do anticorpo, uso de uma combinação do anticorpo e métodos para reduzir a inflamação e para melhorar a descamação e/ou de erupção cutânea e combinação para uso
AR120138A1 (es) Proteínas de fijación multiespecíficas para tratamiento contra el cáncer
MX2022002946A (es) Inhibidores de cdk y su uso como productos farmaceuticos.
BR112015029386A8 (pt) uso de eribulina e lenvatinibe como terapia de combinação, composição farmacêutica compreendendo os mesmos e kit
MX2022001449A (es) Compuestos de aminoesterol humano ent-03, composiciones relacionadas que comprenden los mismos y metodos para usar los mismos.
MX2021004566A (es) Compuestos terapeuticos.
BR112015026247A8 (pt) composto em combinação com um análogo de citidina, composição farmacêutica que os compreende, uso dos mesmos e kit
BR112022000120A2 (pt) Projeto e sínteses eficientes de conjugados de lipídeo-fluoresceína para terapia de células car-t
BR112023018237A2 (pt) Fenalquilaminas e métodos para fabricação e uso das mesmas
WO2019200314A3 (en) Hinokitiol analogues, methods of preparing and pharmaceutical compositions thereof
MX2022002437A (es) Metodos para la produccion de arginasa humana recombinante 1 y sus usos.
EA202091112A1 (ru) Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
MX2021015501A (es) Anticuerpos y metodos de uso.
SA522432999B1 (ar) C-17 مركبات تراي تريبينويد تخليقية ذات مجموعات استبدال اساسها نيتروجين عند وطرق استخدامها

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: ZYMEWORKS BC INC. (CA)